Korro Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRRO research report →
Range $15 – $15
Price Chart
About the company
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
- CEO
- Ram Aiyar
- IPO
- 2019
- Employees
- 58
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on KRRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $167.18M
- P/E
- -1.36
- PEG
- 0.13
- P/S
- 130.67
- P/B
- 2.49
- EV/EBITDA
- -2.33
- Div Yield
- 0.00%
- Gross Margin
- 49.77%
- Op Margin
- -5796.05%
- Net Margin
- -8214.47%
- ROE
- -117.05%
- ROIC
- -54.95%
Latest fiscal year · YoY change
- Revenue
- $6.39M+181.5%
- Gross Profit
- $2.11M-7.0%
- Op Income
- $-87,342,000
- Net Income
- $-117,260,000-40.3%
- EPS
- $-12.48-33.2%
- OCF Growth
- -30.8%
- FCF Growth
- -1.4%
- 52W High
- $17.35
- 52W Low
- $5.20
- 50D MA
- $11.81
- 200D MA
- $12.16
- Beta
- 2.36
- RSI (14)
- 44
- Avg Volume
- 184.81K
No earnings-call transcripts are available for KRRO yet.
- Free Float
- 69.7%
- Shares Outstanding
- 13.73M
- Float Shares
- 9.57M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynx1 Capital Management LP | 1.54M | 0 |
| Nea Management Company, LLC | 1.30M | 0 |
| Venrock Adviser, LLC | 1.01M | 0 |
| Balyasny Asset Management L.P. | 951.78K | ▼ 88.27K |
| Blackrock, Inc. | 844.72K | ▲ 27.10K |
| Atlas Venture Life Science Advisors, LLC | 773.26K | ▼ 189.62K |
| Nantahala Capital Management, LLC | 680.25K | ▲ 20.21K |
| Adage Capital Partners Gp, L.L.C. | 540.97K | ▲ 312.57K |
| Adar1 Capital Management, LLC | 540.05K | 0 |
| Affinity Asset Advisors, LLC | 531.90K | ▼ 175.00K |
| Vanguard Group Inc | 489.64K | ▲ 93.98K |
| Vanguard Capital Management LLC | 477.63K | ▲ 22.85K |
Held by 115 ETFs
Biggest fund positions in KRRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | FORMELA JEAN FRANCOIS | sell | 19,042 |
| Nov 11, 26 | FORMELA JEAN FRANCOIS | sell | 2,984 |
| Nov 12, 26 | FORMELA JEAN FRANCOIS | sell | 33,175 |
| Nov 11, 26 | FORMELA JEAN FRANCOIS | sell | 3,944 |
| Nov 11, 26 | FORMELA JEAN FRANCOIS | sell | 617 |
| Nov 12, 26 | FORMELA JEAN FRANCOIS | sell | 6,870 |
| Oct 26, 26 | Lynx1 Capital Management LP | buy | 25,124 |
| Oct 23, 26 | Lynx1 Capital Management LP | buy | 2,510 |
| Oct 22, 26 | Lynx1 Capital Management LP | buy | 40,000 |
| Oct 22, 26 | Lynx1 Capital Management LP | buy | 12,175 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRRO coverage
Recent articles, reports, and earnings notes.
No research on KRRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRRO report →Korro to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 19
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 13
Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 6
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 5
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Buys 25,124 Shares of Stock
defenseworld.net · Oct 27
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Acquires 52,175 Shares of Stock
defenseworld.net · Oct 27
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
zacks.com · Oct 23
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.